Compare Flagstar Bank NA (FLG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Zoetis Inc — how do they compare? Flagstar Bank NA trades at $14.18 (market cap $5.89B), while Zoetis Inc trades at $73.05 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 5.3× Flagstar Bank NA's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| FLG | ZTS | |
|---|---|---|
Market Cap | $5.89B | $31.14B |
Sector | Financials | Health |
52-Week High | $15.36 | $156.76 |
52-Week Low | $10.72 | $71.91 |
Dividend Yield | 0.28% | 2.81% |
Enterprise Value | — | $38.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $14.20, up 1.36% today, with a bullish technical signal and analyst consensus price target of $16.85 suggesting 19% upside. Recent Q2 2026 earnings missed estimates, but the bank reported its third consecutive profitable quarter, supported by loan growth and cost controls. A $250 million share repurchase program and strategic operational enhancements signal management confidence in long-term value.
The outlook is cautiously optimistic, with profitability improving and valuation attractive at a P/B of 0.77. Risks include earnings volatility, competitive pressures, and economic sensitivity. Institutional sentiment leans bullish, with no sell ratings, though execution on guidance remains key for sustained momentum.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
